Pharmacological activation of the TGF-β signaling pathway using KGN, a small molecule that indirectly enhances TGF-β signaling by regulating the activity of SMAD transcriptional effectors, was used in combination with RA to determine the effect of this dual therapy on NB differentiation and malignancy. Here, TGFB1 is linked to neuroblastoma.